DCGO · CIK 1822359
What DocGo Inc. told the SEC could break it.
DocGo's sharpest disclosed risk is extreme, shifting customer concentration: one customer — a public benefit corporation serving municipal agencies — was about 33% of 2025 revenue, after two customers each topped 28-40% in prior years, so the loss of a key contract would materially dent revenue. Its government ties run deeper through reimbursement: Medicare was about 18.6% of 2025 revenue (and many private payors peg rates to it), exposing it to reimbursement cuts and to Anti-Kickback, Stark and False Claims Act enforcement. Separately, it received a January 2026 Nasdaq notice for falling below the $1.00 minimum bid price, creating a delisting risk if it cannot regain compliance.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- one customer ~33% of revenue (public benefit corp serving municipal agencies)high
DocGo derived ~33% of 2025 revenue from a single customer (a public benefit corporation provisioning services on behalf of municipal agencies under several contracts); in prior years two customers each exceeded 28–40%, indicating extreme, shifting customer concentration.
“We had one customer that accounted for approximately 33% of revenues for the year ended December 31, 2025, two customers that accounted for approximately 38% and 28%, respectively, of revenues for the year ended December 31, 2024, and two customers that accounted for approximately 40% and 21%, respectively, of revenues for the year ended December 31, 20”
SEC filing →As of 2026
Other disclosures
- Nasdaq minimum-bid-price non-compliance (delisting risk)medium
In January 2026 DocGo received a Nasdaq notice that its stock fell below the $1.00 minimum bid price required for continued listing, creating a delisting risk if it cannot regain compliance.
“DocGo is not currently in compliance with Nasdaq Listing Rule 5550(a)(2), which requires DocGo to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market (the “Minimum Bid Requirement”).”
SEC filing →As of 2026
Regulatory & policy
- Medicare reimbursement dependence and healthcare fraud laws (AKS/Stark/FCA)medium
Medicare was ~18.6% of DocGo's 2025 revenue (and many private payors peg rates to Medicare), so reimbursement cuts (e.g. sequestration) hit results; it is also subject to Anti-Kickback, Stark and False Claims Act enforcement with severe penalties.
“Medicare revenues represent approximately 18.6%, 8.9% and 7.7% of DocGo's revenues for the years ended December 31, 2025, 2024 and 2023, respectively.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch